VMA2: A Potential Drug Target for Neurological Disorders and Cancer

Target Name: ATP6V1B1

NCBI ID: G525

ATP6V1B1

VMA2: A Potential Drug Target for Neurological Disorders and Cancer

ATP6V1B1 (VMA2), also known as ATP6V1B1 (VMA2), is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the voltage-dependent rapid transport (VRT) system, which is responsible for the efficient delivery of various molecules across the blood-brain barrier (BBB).

The VRT system is a critical pathway for the transport of neurotransmitters, such as dopamine and GABA, which are involved in various physiological processes, including mood regulation, learning, and memory. The VMA2 protein plays a crucial role in the regulation of VRT, as it is involved in the transport of the neurotransmitter acetylcholine (ACh) across the BBB.

Recent studies have identified VMA2 as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. The reason for this is the accumulation of ACh in the brain, which is thought to contribute to the development and progression of these disorders.

In addition to its role in neurotransmission, VMA2 has also been shown to play a role in the regulation of various cellular processes, including cell signaling, DNA replication, and apoptosis. It has been shown to interact with various protein partners, including the transcription factor NF-kappa-B and the protein kinase PDK4.

The VMA2 protein is also known to be involved in the regulation of cellular processes that are related to the development and progression of cancer. It has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and prostate cancer.

Overall, the VMA2 protein is a promising drug target for various neurological and psychiatric disorders, as well as cancer. Further research is needed to fully understand its role in these processes and to develop effective therapies that target this protein.

Protein Name: ATPase H+ Transporting V1 Subunit B1

Functions: Non-catalytic subunit of the V1 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (PubMed:16769747). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (PubMed:32001091). Essential for the proper assembly and activity of V-ATPase (PubMed:16769747). In renal intercalated cells, mediates secretion of protons (H+) into the urine thereby ensuring correct urinary acidification (PubMed:16769747). Required for optimal olfactory function by mediating the acidification of the nasal olfactory epithelium (By similarity)

The "ATP6V1B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V1B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets